Ellipses Pharma
Business Services · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
10 Stratton St, London, Greater London, ...Phone Number
+44 2037430992Website
ellipses.lifeRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Ellipses Pharma
Ellipses Pharma is a global oncology-focused drug development company based in London, dedicated to accelerating the development of innovative cancer treatments. The company employs a unique drug development model that emphasizes unbiased asset selection and continuous funding to expedite the process. Ellipses Pharma is involved in various collaborations and has a pipeline of first-in-class therapies aimed at addressing unmet clinical needs in oncology. Their mission is to improve patient outcomes through advanced cancer treatment discoveries.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Ellipses Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Ellipses Pharma had a recent Job posting/layoffs
Ellipses Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Ellipses Pharma has new funding data
Website visits: Recent activity has been detected on your website
Check if Ellipses Pharma has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Ellipses Pharma
Check out if Ellipses Pharma is spiking on competitors!
Product Launch: Get notified when Ellipses Pharma launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Ellipses Pharma recently announced quarterly report
Recommended Actions
Find VP level buyers at Ellipses Pharma
Find more new buyers
Compare Similar Companies to Ellipses Pharma
Compare insights from companies similar to Ellipses Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Ellipses Pharma
<$5M
11-50
Private
-
-
N/A
Company Profile Activity
Activity Insights
Ellipses Pharma is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Ellipses Pharma is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Ellipses Pharma.
Ellipses Pharma Tech Stack
A closer look at the technologies used by Ellipses Pharma
Ellipses Pharma News & Media
Ellipses Launches Pioneering Clinical Trial Programme in Middle East
LONDON--(BUSINESS WIRE)--Ellipses Pharma Limited (“Ellipses”), a global drug development company focused on accelerating the development of cancer treatments through an innovative drug development model, announced today it has inaugurated the first large-scale Phase 1/2 oncology clinical study of its kind in the United Arab Emirates, marking a significant milestone in the region’s healthcare landscape. Following approval by the UAE regulators and the Ministry and Department of Health, this studEllipses' next generation selective RET inhibitor EP0031/A400 cleared to start Phase 2
Drug has successfully completed US Food and Drug Administration's End of Phase 1 data review LONDON, May 1, 2024 /PRNewswire/ -- Ellipses Pharma Limited ("Ellipses"), a global drug development company focused on accelerating the development of cancer treatments through an innovative drug...Ellipses EP0031/A400 granted Orphan Drug Designation from the US Food and Drug Administration
EP0031/A400, a next generation selective RET inhibitor (SRI), is currently being investigated as a treatment option for patients with RET altered tumours LONDON, Nov. 23, 2023 /PRNewswire/ -- Ellipses Pharma ("Ellipses"), a global drug development company focused on accelerating the...Ellipses Pharma Announces Intent to Accelerate Clinical Programme Following ‘Encouraging’ Data on Next Generation Selective RET Inhibitor
CHICAGO--(BUSINESS WIRE)--Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of new oncology treatments, today announces its intention to expedite further global clinical development of the next generation selective RET inhibitor (SRI) EP0031/A400 following the publication of ‘very encouraging’ clinical data. Professor Tobias Arkenau, Global Head of Drug Development & CMO at Ellipses, commented: “The data presented today gives everyone in
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding Ellipses Pharma
Sign Up For FreeTo access detailed company insights
Ellipses Pharma is a global oncology-focused drug development company based in London, dedicated to accelerating the development of innovative cancer treatments. The company employs a unique drug development model that emphasizes unbiased asset selection and continuous funding to expedite the process. Ellipses Pharma is involved in various collabor... Read More
